Issue: November 2017
October 02, 2017
1 min read

FDA clears Alere i rapid influenza test

Issue: November 2017
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Alere Inc. announced today that is has received marketing clearance from the FDA for its rapid influenza A and B test, which the company said can produce results in under 5 minutes.

The Alere i Influenza A and B 2 test is a second-generation rapid molecular assay that is cleared for use in adults and children, according to a company press release.

The clinical performance of the test was established during a multicenter trial conducted at 10 sites in the United States during the 2016-2017 influenza season. Researchers used the Alere i Influenza A and B 2 device to evaluate 1,074 nasal or nasopharyngeal swab specimens collected from patients with influenza-like symptoms and compared its accuracy with an FDA-cleared real-time PCR test.

“In acute care settings, every minute counts when assessing symptomatic patients,” Avi Pelossof, global president of infectious diseases at Alere, said in a press release. “Alere i delivers clinically meaningful and actionable results to clinicians — enabling them to treat patients more quickly and appropriately.”

The original Alere i A and B molecular influenza test was cleared by the FDA in June 2014 as a prescription-only device for use in certain laboratories. In January 2015, the FDA granted a Clinical Laboratory Improvement Amendments (CLIA) waiver that allowed the test to be used at the point of care. The company plans on submitting another CLIA waiver for the Alere i A and B 2 test, which has additional features, including bidirectional connectivity and a quality control lockout option that prevents the testing of samples if quality control requirements are not met, the release said. In addition to the Alere i influenza test, the FDA also granted CLIA waivers for Alere i Strep A and RSV tests.

“Our innovative Alere i platform leads the way in the rapid molecular segment with thousands of placements in hospitals, clinics, physician offices and other point-of-care settings,” Pelossof said in the release. “With this latest enhancement, we now can offer ‘early call out’ of positive results on all three available applications, Alere i Influenza A and B 2, Alere i Strep A and Alere i RSV.”

Disclosure: Pelossof is an employee of Alere.